Seven Wall Street Firms Lower Coinbase Targets After Q3 Print
Seven Wall Street firms cut Coinbase price targets after Q3 earnings, citing weak trading fees; the stock fell 6% premarket.
Elon Musk showcased new Neuralink demos on Oct. 30. The company remains private and most investors have no regulated way to buy shares.
Elon Musk provided a new catalyst for investors curious about buying into Neuralink. On Oct. 30, the billionaire released demonstrations of the brain-chip, featuring a mind-operated Grok tool and text-to-speech capabilities sent to iPhone calls. Despite this, the vast majority of non-US retail investors are unable to get in.
Telepathy, the company’s debut product, allows individuals to interact with machines or other people simply by thinking, Musk reiterated. He forecast that its data-transfer speed would far surpass the quickest human conversation or keyboard input within a matter of years.
The features were built during a 72-hour hackathon involving a participant in a speech restoration trial, according to Musk’s post. With the Grok functionality, the user mentally utters “Hey Neuralink” combined with a request.
For the calling function, the team uses Bloom, its newly developed smartphone speech programme. According to the group, the user’s mental speech is channeled directly into the phone call’s audio stream.
Neuralink’s first product is called Telepathy.
— Elon Musk (@elonmusk)
It enables high-speed communication with computers or humans simply by thinking. Output bandwidth will vastly exceed the fastest human speech or typing in a few years. Read that sentence again. https://t.co/cv1KCA076q
Looking past communication, the co-founder of Neuralink aims for the technology to direct neural signals to the arms and legs. Such a development would potentially restore hand function and walking ability.
The company’s devices have not yet received FDA clearance, and Musk has previously missed his own deadlines for the firm. Nonetheless, Neuralink secured a valuation of $9 billion in its most recent financing round. That figure accounts for the intense interest from retail investors.
As a private company, Neuralink’s stock is not listed on any public market. This situation offers limited choices. Pre-IPO platforms do trade holdings in non-public companies, but they generally restrict access to accredited investors.
The principal regulated avenue for common investors is the ARK Venture Fund (ARKVX), managed by ARK Invest. This fund contains a stake in Neuralink and is accessible to any US investor. ARK has stated, however, that it is currently closed to overseas investors.
This drives numerous non-US retail investors towards crypto offerings, which entail significantly greater risk. The Solana-based PreStocks platform features a Neuralink token, joining a rising category of pre-IPO tokens. The token surged to an all-time high near the moment of Musk’s announcement, subsequently retracing a portion of the move.
Yet, the token’s market cap sits at roughly $1 million. With such shallow liquidity, a small number of transactions can drastically affect the price, rendering it susceptible to market abuse. PreStocks asserts that its tokens are underpinned by indirect exposure to the company’s equity via special purpose vehicles. The reporting outlet could not independently verify this assertion. Irrespective of this, holders possess no actual Neuralink shares or accompanying shareholder entitlements. Furthermore, there is no indication that Neuralink has authorized the offering.
Additional risk comes from imitation memecoins that exploit the Neuralink name, a recurring trend. These tokens are unaffiliated with both the company and PreStocks. Anyone aiming to gain exposure via the PreStocks token ought to verify the contract address thoroughly. Comparable pre-IPO instruments are expanding, with Binance Wallet also intending to launch pre-IPO token trades, also offering no direct shareholder rights. Unless and until Neuralink conducts a public listing, the majority of non-US investors lack a fully regulated entry point.
Share to
Disclaimer: this article comes from third-party media and is provided for reference only. It does not constitute investment advice. Crypto and other financial products carry significant price volatility risk, so please make your own decisions carefully.
Seven Wall Street firms cut Coinbase price targets after Q3 earnings, citing weak trading fees; the stock fell 6% premarket.
Strategy's Q3 2026 earnings call featured an analyst Q&A with Phong Le and Michael Saylor covering digital credit, STRC, and Bitcoin tokenization.
The Nasdaq Composite fell 5.30% in October, its worst month since March 2025, as technology stocks tumbled.
AstraZeneca shares rose nearly 7% after a Q3 earnings beat and a $1.5B savings plan; cancer drugs powered growth.